CalciMedica
CALCCalciMedica is a clinical-stage biopharmaceutical company developing a new class of small-molecule therapeutics that target calcium release-activated calcium (CRAC) channels.
Earnings
Next report
Nov 11, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
CalciMedica is a clinical-stage biopharmaceutical company developing a new class of small-molecule therapeutics that target calcium release-activated calcium (CRAC) channels. The company's platform addresses serious inflammatory and immunologic illnesses by modulating inflammatory signaling and protecting tissue cells from calcium-mediated injury. Its lead development programs focus on acute critical care settings where there are currently no approved disease-modifying therapies.
A pioneer in CRAC channel inhibition with a first-in-class clinical candidate targeting acute pancreatitis and other critical care indications.
FAQ
- What is CalciMedica's market cap?
- CalciMedica (CALC) has a market capitalization of $18.1M and trades on NASDAQ.
- Who are CalciMedica's competitors?
- CalciMedica's key competitors include Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., CorMedix Inc., and others. These companies compete in similar markets and product categories.
- Who does CalciMedica partner with?
- CalciMedica's notable partners include St. Jude Children's Research Hospital, Charité – University Medicine Berlin, New York University Grossman School of Medicine, and others.
- Where is CalciMedica headquartered?
- CalciMedica is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2020.